MC
MNTA

Marcus Capital’s Momenta Pharmaceuticals, Inc. MNTA Stock Holding History

Marcus Capital’s Portfolio MNTA Stock Details MNTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-50,400
Closed -$932K – 47
2017
Q3 		$932K Sell
50,400
-53,600
-52% -$896K 1.32% 33
2017
Q2 		$1.76M Buy
104,000
+5,200
+5% +$79.1K 1.51% 34
2017
Q1 		$1.32M Buy
+98,800
New +$1.55M 1.23% 37

Other funds holding MNTA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Marcus Capital's MNTA Position: Q4 2017 in Review

Marcus Capital sold out of Momenta Pharmaceuticals, Inc. (MNTA) in Q4 2017, closing a stake of 50,400 shares — an estimated $932K sold.

Marcus Capital first reported a position in MNTA in Q1 2017 and held it in 3 quarters. The position peaked at $1.76M in Q2 2017. 166 funds tracked by Wall St. Rank hold MNTA as of Q4 2017.

  • Marcus Capital reported no remaining Momenta Pharmaceuticals, Inc. position as of Q4 2017 after selling out during the quarter.
  • Marcus Capital sold 50,400 Momenta Pharmaceuticals, Inc. shares in Q4 2017, an estimated $932K.
  • Marcus Capital first reported a position in Momenta Pharmaceuticals, Inc. in Q1 2017 and held it in 3 quarters.
  • Marcus Capital's Momenta Pharmaceuticals, Inc. position peaked at $1.76M in Q2 2017.
  • 166 funds tracked by Wall St. Rank held Momenta Pharmaceuticals, Inc. as of Q4 2017.

Based on Marcus Capital's 13F filing for Q4 2017, filed 7 Feb 2018.